Radiation-induced morphea—a rare but severe late effect of adjuvant breast irradiation

Case report and review of the literature

Richard Partl1 · Peter Regitnig2 · Gerlinde Tauber1 · Michaela Pötscher1 · Vesna Bjelic-Radisic3 · Karin S. Kapp1

Received: 13 February 2018 / Accepted: 4 July 2018 / Published online: 16 July 2018
© The Author(s) 2018

Abstract

Background Radiation-induced morphea (RIM) is a circumscribed localized scleroderma that occurs most often in the breast. After an asymptomatic period of one month to several years, the symptoms (circumscribed inflammation, edema, sclerosis) often arise suddenly and cannot be clinically distinguished from a local recurrence in the form of inflammatory carcinoma.

Case We present a case of a 74-year-old woman who developed this rare and serious local side-effect in connective tissue following neoadjuvant CDK 4/6 inhibitor abemaciclib (Verzenio®) and aromatase inhibitor anastrozole (Arimidex®) therapy and subsequent radiation therapy of the breast.

Conclusions Little is known about risk factors and pathogenesis of RIM. Here we describe the first case of RIM following immunotherapy. The diagnosis is based on clinical appearance and histopathological examination. Treatment should be initiated in the inflammatory stage in order to prevent or delay irreversible fibrosis and atrophy of the breast.

Keywords Morphea · Radiotherapy · Scleroderma, localized · Side-effect · Breast cancer

Strahleninduzierte Morphea – eine seltene, aber schwere späte Folge der adjuvanten Brustbestrahlung
Fallbericht und Literaturübersicht

Zusammenfassung

Hintergrund Die strahleninduzierte Morphea (RIM) ist eine lokale begrenzte Sklerodermie mit bevorzugter Lokalisation in der Brust. Nach einem beschwerdefreien Intervall von einem Monat bis mehreren Jahren treten die Symptome (umschriebene Entzündung, Ödem, Sklerose) häufig abrupt auf und sind klinisch nicht von einem Lokalrezidiv im Sinne eines inflammatorischen Karzinoms zu unterscheiden.

Karlin S. Kapp
karin.kapp@medunigraz.at

1 Department of Therapeutic Radiology and Oncology,
Comprehensive Cancer Center (CCC), Medical University of Graz, Auenbruggerplatz 32, 8036 Graz, Austria

2 Institute of Pathology, Comprehensive Cancer Center (CCC),
Medical University of Graz, Auenbruggerplatz 25, 8036 Graz, Austria

3 Division of Gynecology, Comprehensive Cancer Center (CCC), Medical University of Graz,
Auenbruggerplatz 14, 8036 Graz, Austria

Springer
Fallbericht Wir berichten den Fall einer 74-jährigen Patientin, die nach neoadjuvanter Behandlung mit dem CDK 4/6 Inhibitor Abemaciclib (Verzenio®) und dem Aromataseinhibitor Anastrozol (Arimidex®) sowie adjuvanter Radiotherapie der Brust diese schwere lokale Nebenwirkung des Bindegewebes entwickelte.

Schlussfolgerung Risikofaktoren für die Entstehung einer RIM sowie deren Pathogenese sind noch weitgehend unklar. Wir beschreiben den ersten Fall einer RIM nach Immuntherapie. Die Diagnose wird anhand des klinischen Verlaufs und der histologischen Untersuchung gestellt. Die Behandlung sollte bereits im inflammatorischen Stadium eingeleitet werden, um eine irreversible Fibrose und Atrophie der Brust abzuwenden oder zu verzögern.

Schlüsselwörter Morphea · Bestrahlung · Lokalisierte Sklerodermie · Nebenwirkung · Brustkrebs

Introduction

Reversible acute skin changes within the radiation field (NTC grade 1 or 2) are common side-effects induced by radiation of the breast with an incidence of >90% [1]. Irreversible late effects (telangiectases, subcutaneous indurations, liponecrosis, fibrosis) are rare in connection with modern irradiation techniques. Radiation-induced morphea (RIM) is distinct from these and is a rare and often unrecognized local and chronically progressive radiation-associated scleroderma of the skin [2, 3]. Clinical and surgical oncologists should bear this condition in mind because only a rapid diagnosis and treatment of RIM can stop or delay the progress of irreversible fibrosis of the cutis and subcutis and thus improve the quality of life for the patients. Here we report the case of a patient who developed an early and extensive RIM of the breast following therapy with neoadjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor and aromatase inhibitor (anastrozole, Arimidex®), segmental resection and adjuvant radiotherapy.

Case presentation, clinical follow-up, and examination findings

In October 2015, in the course of a routine mammography and sonography, a 72-year-old woman was diagnosed with a centrally located carcinoma of the right breast with enlarged axillary lymph nodes. The pretherapeutic staging tests and anamnesis were unremarkable apart from hypertension, obesity and smoking and there was no history of allergy. In particular, there were no signs of an autoimmune disease.

Based on the clinically positive axilla of a cT1 tumor (invasive carcinoma of no special type, G1, hormone receptor positive, Her2/neu negative, Ki67 10%), the patient was given a 4-month neoadjuvant systemic therapy with the nonsteroidal aromatase inhibitor anastrozole (Arimidex®) and the CDK 4/6 inhibitor abemaciclib (Verzenio®), from November 2015 to March 2016, as part of a clinical trial (NeoMONARCH).

The histopathological work-up of the surgical specimen revealed stage ypT1b ypN0 R0 disease. Following segmentectomy and sentinel node dissection, adjuvant radiotherapy (RTX) of the right breast and the supraclavicular region was done in three-dimensional (3D) conformal technique up to a total dose of 50 Gy (6MV) in 25 fractions with an electron boost dosage to the tumor bed of 10 Gy (16 MeV) in 5 fractions while continuing therapy with anastrozole. Prior to radiotherapy the measured volume of the irradiated right breast revealed no difference compared with the left side (1455 vs. 1500 ccm; Fig. 1). Towards the end of the course of radiation, the patient developed a moderate acute radio-dermatitis with small circumscribed moist epitheliolysis in the submammary fold, which were classified as CTCAE grade 2 and treated symptomatically for the remaining period of radiotherapy.

Three months after completion of RTX, all acute skin changes had completely healed, but a new, 2 cm wide, circumscribed cutis edema was observed at 1 o’clock within the irradiated breast and was documented. Six months after RTX, this developed into an increasing local redness and induration of the skin. A cutis edema was visible in sonography, which showed that the changes were limited to the irradiation field. Nine months after RTX, the cutis edema...
Fig. 2  a Haematoxylin and eosin stained section of the deep punch biopsy showing massive fibrosis of dermis (red stained areas) and pronounced perivascular and subcutaneous inflammatory infiltrate (blue stained areas). b Magnification of Fig. 2a at the interphase between dermis and subcutis: Lymphoid infiltrate on dermal site and histiocytic infiltrate towards adipocytes with consumption of adipocytes and increase of collagen. At the bottom loosely cohesive collagen and towards the dermis increasing thick and dense collagen bundles had grown to cover the whole former irradiation field, the skin exhibited a continuous inflammatory infiltrate, hyperpigmentation and induration. A loss of breast volume was also clearly evident. To rule out a lymphangiosis carcinomatosa cutis (inflammatory carcinoma) recurrence, a targeted punch biopsy was performed. The histology showed no signs of malignant tumor cells but a pronounced dermal fibrosis with thickened dermis and fibrosis extending into the underlying fatty tissue, with corresponding panniculitis and pronounced chronic perivascular inflammation (Fig. 2a, b).

Based on the pronounced clinical picture (Fig. 3) and the distressing situation for the patient, the histological findings from February 2017 were re-examined. Taking account of the radiation history and the clinical progression, a postradiogenic circumscribed scleroderma (morphea) was diagnosed in December 2017, 20 months after RTX.

After the diagnosis had been established all suggested treatments which included systemic immune suppression with steroids and methotrexate (MTX) were declined by our patient. She has been applying topical steroids and has undergone several weeks of lymph drainage at a specialized center. The clinical picture has remained unchanged since December 2017.

Discussion and literature review

Radiation-induced morphea (RIM), also known in the literature under the names postirradiation morphea (PIM), radiation-induced scleroderma, radiation port morphea, radiation port scleroderma, localized scleroderma and circumscribed scleroderma, is a chronic inflammatory condition of the skin and underlying tissue which results in a fibrotic transformation and in very rare cases may involve fascia and bone. Bleasel et al. [2] and Davis et al. [4] each describe frequencies of 1:500 irradiated breast cancer patients. In the nonirradiated population, an incidence of 2.7:100,000 persons per year has been reported [5]. The difference in incidence strongly suggests that radiotherapy is a risk factor. However, since 1989 [6] only 81 cases of RIM have been described in the literature. If the reported frequency of 1:500 irradiated breast cancer patients holds true, a significant number of patients developing RIM have gone undiagnosed or misdiagnosed and may have received no or inappropriate treatment. In a recent report, Friedman et al. [7] described 3 cases of RIM in 12,000 breast cancer patients treated with adjuvant radiotherapy resulting in an estimating prevalence of 1:3000 cases. The onset of RIM in these patients was 4, 5, and 7 years, respectively.

Of note is the fact that the large majority of reports relate to adjuvant radiotherapy of the breast. The numbers of cases reported in connection with head and neck cancer [8], endometrial carcinoma [9], vulva [10] or lymphomas [11] are significantly smaller. A pragmatic explanation might be the ease of clinical diagnosis and of the comparison between the irradiated and nonirradiated breast [12].
Table 1 Published reports on localized morphea after adjuvant irradiation of the breast since 1998

| Author                          | No. of cases | Time interval between radiotherapy and onset | Prior systemic treatment                      |
|--------------------------------|--------------|---------------------------------------------|-----------------------------------------------|
| Gollob et al. (1998) [29]      | 1            | 1 < year                                    | Not recorded                                  |
| Bleasel et al. (1999) [2]      | 4            | 1 < year                                    | 2 cases: tamoxifen; 2 cases: no systemic treatment |
| Fischer et al. (1999) [25]     | 1            | 14 years                                    | Not recorded                                  |
| Schaffer et al. (2000) [20]    | 2            | 6.5–32 years                                | 1 case: tamoxifen; 1 case: not recorded        |
| Ullen and Björkholm (2003) [9] | 1            | 2 months                                    | Not recorded                                  |
| Ardern-Jones and Black (2003)  | 1            | 13 years                                    | Tamoxifen                                     |
| Reddy et al. (2005) [31]       | 1            | <1 year                                     | Tamoxifen                                     |
| Dubner et al. (2006) [32]      | 1            | 3 years                                     | Chemotherapy (not specified)                  |
| Dancey and Waters (2006) [33]  | 1            | <1 year                                     | Not recorded                                  |
| Seale et al. (2008) [34]       | 1            | 2 years                                     | Doxorubicin, cyclophosphamide                 |
| Walsh et al. (2008) [35]       | 5            | 4–12 years                                  | 1 case: antiestrogen treatment; 4 cases: no treatment |
| Cheah et al. (2008) [36]       | 1            | 9 months                                    | Tamoxifen                                     |
| Herrmann et al. (2009) [11]    | 1            | 1.5 years                                   | Anti-hormonal therapy                         |
| Morganroth et al. (2010) [37]  | 1            | 6 years                                     | Doxorubicin, cyclophosphamide, paclitaxel     |
| Laetsch et al. (2011) [38]     | 3            | <1 year                                     | 1 case: doxorubicin and cyclophosphamide, tamoxifen; 2 cases: no systemic treatment |
| Wernicke et al. (2011) [39]    | 1            | 1.5 years                                   | Tamoxifen                                     |
| Alhathlool et al. (2012) [40]  | 1            | 2.7 years                                   | Anastrozole                                   |
| Lim et al. (2014) [41]         | 1            | 7 months                                    | Epirubicin, cyclophosphamide, docetaxel       |
| García-Arpa et al. (2015) [42] | 1            | 1 year                                      | Chemotherapy (not specified), letrozole       |
| Yanaba et al. (2015) [43]      | 1            | 3 months                                    | Not recorded                                  |
| Dyer et al. (2016) [44]        | 2            | 3–4 months                                  | 1 case: chemotherapy (not specified)          |
| Chu et al. (2017) [45]         | 1            | 10 months                                   | Not recorded                                  |
| Gonzalez-Ericsson et al. (2018)| 1            | 1.3 years                                   | Cisplatin, paclitaxel                         |
| Friedman et al. (2018) [7]     | 3            | 4, 5, 7 years                                | Case 1: neoadjuvant chemotherapy (not specified), adjuvant tamoxifen; case 2: adjuvant tamoxifen; case 3: non |
| Peterson et al. (2018) [23]    | 1            | 5 months                                    | Not recorded                                  |
| Papanikolaou et al. (2018) [27]| 1            | 4 months                                    | Not recorded                                  |
| Partl et al. (current report)  | 1            | 3 months                                    | Anastrozole, CDK4/6 inhibitor (abemaciclib)   |

theory suggests that the cause is the inclusion of substantial dermal and subdermal tissue in the irradiated volume [13]. Table 1 summarizes the cases of RIM reported after adjuvant irradiation of the breast over the last 20 years.

Currently no predictive model for the risk of developing RIM exists. There is no relationship with the radiation parameters such as total dose and single dose [2], with acute radiation side effects, age, neoadjuvant or concomitant systemic cancer therapy [14]. In patients with systemic sclerosis there is no evident difference with respect to acute skin toxicity, which are known to carry a significantly higher risk of developing chronic side-effects compared to the control group (29.1% vs. 14%; p = 0.001) [15, 16]. This means that the decision on whether to use RTX needs to be made carefully and that the risk should be discussed with all patients diagnosed with systemic sclerosis.

Our patient received neoadjuvant treatment with the CDK4/6 inhibitor abemaciclib (Verzenio®). CDK 4 and 6 regulate the transition from the G1 to S phase through the inhibition of the tumor suppressor function of the retinoblastoma protein. The novel cancer therapeutic abemaciclib is a highly selective reversible inhibitor of these enzymes and received FDA Breakthrough Therapy designation in October 2015. Its cell cycle inhibition is based on the liberation of the tumor suppressor retinoblastoma protein from the inhibitory effect of the cyclin-dependent kinase [17, 18]. At present it is unclear whether the pathology described in our case report is related to the neoadjuvant CDK 4/6 inhibitor. Nonomura et al. however postulated that cyclin-dependent kinase 4/6 proteins can modulate the production of inflammatory molecules through multiple pathways in patients with rheumatoid arthritis [19]. The fact that interactions of the newest generation of medicines have not been tested prospectively makes it even more important to record and report such side-effects that arise in combination with radiotherapy.

Usually the symptoms of RIM manifest within a year after the end of radiotherapy, but both short and very long
intervals, from one month to 32 years, have been described [20]. Typically, following a variable period of asymptomatic latency, there is an abrupt onset of edematous and erythematous plaques (initial inflammatory phase). The subsequent sclerotic phase is mainly characterized by painful induration of the irradiated breast, followed by fibrotic retraction and hyperpigmentation. The changes are usually limited to the area of the irradiated area but in rare cases can extend beyond this area [3, 21] or even become generalized [22]. Peterson et al. presented an unusual overlap of morphea and lichen sclerosus. Both skin disorders are considered inflammatory autoimmune phenomena favoring distinct tissue planes [23].

Diagnosis is done by biopsy. Histologically, in the inflammatory phase dermal perivascular and interstitial inflammatory infiltrates are found. In the sclerotic phase a sclerotic reorganization of the tissue due to an increase of collagen occurs. The epidermis remains uninvolved. In the inflammatory phase the differential diagnosis must consider an infection, a “radiation recall reaction” and an inflammatory tumor recurrence. In the “burn-out phase” a chronic radiodermatitis and a related postradiogenic fibrosis are possible.

The pathomechanism for the development of RIM is not fully understood. It is hypothesized to be a disorder of immune regulation against the background of a genetic predisposition. A trigger (e.g., irradiation, infection, trauma) activates expression of cytokines (IL 4, 5) and transforming growth factor-β (TGF-β), which leads to an activation of fibroblasts and an increase in collagen synthesis [4, 11]. TGF-β induces an excessive transformation of CD34-positive fibroblast precursor cells into myofibroblasts. This in turn leads to a thickening and sclerosis of the connective tissue. Through a positive feedback mechanism, TGF-β stimulates its own synthesis [24].

Treatment depends on the stage of the inflammation. In the acute inflammation phase immunosuppressive drugs are recommended. As a first-line therapy, topical application of calcineurine inhibitors (tacrolimus ointment) and topical steroids are recommended. Systemic immune suppression with steroids, MTX und cyclosporine can also be used. For symptomatic improvement of the fibrosis, some authors recommend local application of heparin, hyaluronidase [25], ultraviolet A irradiation [26] or penicillin (3 × 10^6 IU daily for two weeks). In another case report photodynamic therapy is suggested as a successful treatment option [27]. Testing of the different therapy options in the largest RIM cohorts to date showed the best response to systemic treatment with MTX or ultraviolet-B phototherapy [28].

Treatment should begin immediately after diagnosis in the inflammatory stage in order to prevent or delay irreversible fibrosis and atrophy.

Conclusions

RIM is a rarely described, serious and unpredictable late side-effect with a large variability in the timing of onset. Practitioners in oncology should consider this diagnosis early and should carry out appropriate tests to exclude infection, an inflammatory recurrence of cancer, a radiation recall phenomena, postradiogenic fibrosis or chronic radiodermatitis. After histological confirmation of RIM, it is important to begin local and systemic therapy as soon as possible in order to limit the progress of fibrosis and atrophy and to improve the patient’s quality of life.

Funding

Open access funding provided by Medical University of Graz.

Conflict of interest

R. Partl, P. Regitnig, G. Tauber, M. Pötscher, V. Bjelic-Radisic and K.S. Kapp declare that they have no competing interests.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Harper JL, Franklin LE, Jenrette JM, Aquero EG (2004) Skin toxicity during breast irradiation: pathophysiology and management. South Med J 97:989–993
2. Bleasel NR, Stapleton KM, Commens C, Ahern VA (1999) Radiation-induced localized scleroderma in breast cancer patients. Australas J Dermatol 40:99–102
3. Akay BN, Sanli H, Heper AO (2010) Postirradiation linear morphea. Clin Exp Dermatol 35:106–108
4. Davis DA, Cohen PR, McNeese MD, Duvic M (1996) Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 35:923–927
5. Ardern-Jones MR, Black MM (2003) Widespread morphea following radiotherapy for carcinoma of the breast. Clin Exp Dermatol 28:160–162
6. Colver GB, Rodger A, Mortimer PS et al (1989) Post-irradiation morphea. Br J Dermatol 120:831–835
7. Friedman O, Barnea Y, Hafner A (2018) Underdiagnosed and disfiguring—radiation-induced morphea following breast cancer treatment. Breast 39:97–100. https://doi.org/10.1016/j.breast.2018.04.006
8. Cooper SG, Denham JW (1990) Progressive systemic sclerosis (diffuse scleroderma) and radiotherapy. Br J Radiol 63:804–805
9. Ullen H, Bjorkholm E (2003) Localized scleroderma in a woman irradiated at two sites for endometrial and breast carcinoma: a case history and a review of the literature. Int J Gynecol Cancer 13:77–82
10. Edwards LR, Privette ED, Patterson JW, Tchernev G, Chokoova A, Wollina U, Lotti T, Wilson BB (2017) Radiation-induced lichen sclerosus of the vulva: first report in the medical literature. Wien Med Wochenschr 167:74–77
11. Smith KJ, Yeager J, Shelton HG, Cohen PR, Davis DA, Duvic M (1997) Localized scleroderma in breast cancer patients treated with...
